Regulatory Roundup: Device Ban Supported; Obesity Device Panel; Eyelid Weights
This article was originally published in The Gray Sheet
Executive Summary
FDA neuro panel supports FDA’s proposed ban of electrical stimulation devices used for “aversive conditioning.” The agency has officially scheduled an advisory panel meeting to consider EnteroMedics’s PMA for the implantable Maestro Rechargeable System as a weight-loss tool in obese patients. More regulatory news.
You may also be interested in...
FDA’s Upcoming Drug/Diagnostic Co-Development Guidance Could Quickly Become Outdated
Tests that look for many markers at a time “may completely change” the paradigm for companion diagnostics, CDRH’s Elizabeth Mansfield says.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.